SQA
ACOR

Simon Quick Advisors’s Acorda Therapeutics ACOR Stock Holding History

Simon Quick Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-719
Closed -$8.42K – 299
2023
Q1 		$8.42K Buy
719
+8
+1% +$133 ﹤0.01% 277
2022
Q4 		$10.9K Hold
711
– – ﹤0.01% 245
2022
Q3 		$4K Hold
711
– – ﹤0.01% 203
2022
Q2 		$6K Buy
+711
New +$12.6K ﹤0.01% 178

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Simon Quick Advisors's ACOR Position: Q2 2023 in Review

Simon Quick Advisors sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 719 shares — an estimated $8.42K sold.

Simon Quick Advisors first reported a position in ACOR in Q2 2022 and held it in 4 quarters. The position peaked at $10.9K in Q4 2022. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.

  • Simon Quick Advisors reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Simon Quick Advisors sold 719 Acorda Therapeutics shares in Q2 2023, an estimated $8.42K.
  • Simon Quick Advisors first reported a position in Acorda Therapeutics in Q2 2022 and held it in 4 quarters.
  • Simon Quick Advisors's Acorda Therapeutics position peaked at $10.9K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.

Based on Simon Quick Advisors's 13F filing for Q2 2023, filed 1 Aug 2023.